Table 6 SuS disease damage score at last visit
Patient 1 | Patient 2 | |
|---|---|---|
Neurologic damage subscore (0–1700)*: | 12 (13)** | 325 |
Decreased mental alertness (0–100) | 2 (2) | 20 |
Slow thought processing (0–100) | 2 (3) | 10 |
Memory impairment (0–100) | 0 (0) | 20 |
Intellectual impairment | ||
Affecting school/work (0–100) | 4 (3) | 50 |
Decreased executive function (0–100) | 0 (0) | 65 |
Emotional lability (0–100) | 0 (0) | 30 |
Personality change (0–100) | 0 (0) | 25 |
Confusion/odd behavior (0–100) | 0 (0) | 25 |
Poor concentration (0–100) | 4 (5) | 50 |
Unsteady gait (0–100) | 0 (0) | 0 |
Spasticity (0–100) | 0 (0) | 0 |
Gross motor impairment (0–100) | 0 (0) | 10 |
Fine motor impairment (0–100) | 0 (0) | 10 |
Hemiparesis (0–100) | 0 (0) | 10 |
Neurogenic bladder (0–100) | 0 (0) | 0 |
Neurogenic bowel (0–100) | 0 (0) | 0 |
Slurred speech (0–100) | 0 (0) | 0 |
Inner ear damage subscore (0–600): | 0 (0) | 120 |
Hearing loss (H/L) R (0–100) | 0 (0) | 40 |
Hearing loss L (0–100) | 0 (0) | 50 |
Tinnitus R (0–100) | 0 (0) | 0 |
Tinnitus L (0–100) | 0 (0) | 0 |
Vertigo (0–100) | 0 (0) | 0 |
H/L adversely affecting QOL (0–100) | 0 (0) | 30 |
Eye damage subscore (0–500): | 0 (0) | 0 |
Permanent blind spot R (0–100) | 0 (0) | 0 |
Permanent blind spot L (0–100) | 0 (0) | 0 |
Constricted peripheral vision R (0–100) | 0 (0) | 0 |
Constricted peripheral vision L (0–100) | 0 (0) | 0 |
Visual damage affecting QOL | 0 (0) | 0 |
Total disease damage score (0–2800): | 12 (13) | 445 |
Global assessment of disease damage (0–100): | 2 (5) | 60 |